H04.15 Secondary lacrimal gland atrophy

Name of the Condition

• Secondary Lacrimal Gland Atrophy (ICD-10 code: H04.15)

Summary

Secondary lacrimal gland atrophy refers to the degeneration or shrinkage of the lacrimal gland due to an underlying condition or external factor, rather than a primary disorder of the gland itself. This condition can reduce tear production, leading to dry eye symptoms or other ocular complications. The lacrimal gland is critical for maintaining ocular surface health, and its atrophy may impact tear quality or quantity.

Causes

Causes include systemic diseases, chronic inflammation, or external factors that affect gland function. Examples are autoimmune disorders (e.g., Sjögren's syndrome), infections, radiation exposure, or trauma to the gland. Certain medications or surgical interventions near the gland may also contribute to secondary atrophy.

Risk Factors

Risk factors depend on the underlying cause but may include a history of autoimmune disease, prior radiation therapy to the head or eye area, chronic inflammatory conditions, or prolonged use of medications that suppress gland function. Age-related changes or genetic predisposition to gland degeneration may also play a role.

Symptoms

Symptoms can include persistent dry eye, eye irritation, redness, or a sensation of grittiness. Reduced tear production may lead to discomfort, blurred vision, or increased sensitivity to light. In some cases, patients may experience excessive tearing as a reflex response to dryness.

Diagnosis

Diagnosis involves a clinical evaluation, including a review of symptoms and ocular surface assessment. Tests such as tear production measurements (e.g., Schirmer test) or imaging studies (e.g., MRI) may be used to evaluate gland structure. Underlying causes are investigated through history, physical exam, or additional testing.

Treatment Options

Treatment focuses on managing symptoms and addressing the underlying cause. Artificial tears or lubricating eye drops may alleviate dryness. In cases of inflammation, anti-inflammatory medications or immunosuppressants may be prescribed. If an underlying condition is identified, targeted therapy for that condition is essential.

Prognosis and Follow-Up

Prognosis depends on the underlying cause and response to treatment. Early intervention can help manage symptoms, but gland function may not fully recover in severe cases. Regular follow-up with an eye care provider is recommended to monitor tear production and adjust treatment as needed.

Complications

Complications may include chronic dry eye, corneal damage, or increased risk of eye infections due to reduced tear protection. Severe atrophy can lead to persistent discomfort or vision impairment if left untreated.

Lifestyle & Prevention

Lifestyle measures include using humidifiers to reduce environmental dryness, avoiding irritants (e.g., smoke), and taking breaks during prolonged screen use. Protective eyewear may help prevent trauma. Managing underlying conditions (e.g., autoimmune disease) can reduce the risk of progression.

When to Seek Professional Help

Seek care if symptoms worsen, persist despite home measures, or if vision changes occur. Prompt evaluation is important if dryness leads to pain, redness, or discharge, as these may indicate infection or other complications.

Tips for Medical Coders

Document the underlying cause or contributing factor when coding H04.15, as secondary atrophy requires specification of the associated condition. Ensure clinical notes support the diagnosis and any related interventions. Verify that the code is not used for primary lacrimal gland disorders, which have distinct codes.